Adrenocortical Carcinoma Pipeline

DelveInsight’s, “Adrenocortical Carcinoma - Pipeline Insight, 2025” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Adrenocortical Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Geography Covered

• Global coverage

 

Adrenocortical Carcinoma: Understanding

Adrenocortical Carcinoma: Overview

Adrenocortical carcinoma (ACC) is a rare and aggressive malignancy arising from the adrenal cortex, the outer portion of the adrenal glands situated atop the kidneys. These glands play a vital role in endocrine function by producing essential steroid hormones including cortisol, aldosterone, and androgens. The annual incidence of ACC is estimated to be between 0.7 to 2 cases per million population. ACC exhibits a bimodal age distribution, with peaks in early childhood (often associated with genetic syndromes) and in adults aged 30–40 years. Due to its aggressive biological behavior, ACC often presents at an advanced stage, contributing to its poor prognosis.

The clinical presentation of ACC depends on whether the tumor is functioning or non-functioning. Functioning tumors are more common and lead to hormone-related syndromes such as Cushing’s syndrome, virilization, or feminization due to excess cortisol, androgens, or estrogens. Aldosterone-secreting tumors may cause hyperaldosteronism, resulting in hypertension and electrolyte imbalances. Non-functioning tumors typically remain asymptomatic until they enlarge and cause abdominal discomfort or are incidentally detected at an advanced stage.

The pathogenesis of ACC involves genetic and molecular alterations that disrupt cell cycle control and steroid hormone production. Key mutations include TP53, commonly seen in Li-Fraumeni syndrome, especially in pediatric cases, and CTNNB1, affecting the Wnt/β-catenin signaling pathway, which promotes tumor progression. Other important changes involve IGF2 overexpression, and mutations in MEN1 and PRKAR1A genes. These alterations result in unchecked cell growth, resistance to apoptosis, and abnormal steroidogenesis, contributing to the aggressive and diverse nature of ACC. The diagnosis of adrenocortical carcinoma (ACC) requires a multi-disciplinary approach integrating clinical signs, hormone evaluation, imaging, and pathology. Patients may present with hormone-related symptoms like Cushing’s syndrome or virilization, or with nonspecific abdominal complaints; some tumors are found incidentally. Hormonal tests, including serum cortisol, ACTH, adrenal androgens, dexamethasone suppression, and 24-hour urine steroid profiling, are essential. Imaging—primarily abdominal CT—is used to assess tumor size and features, while MRI and FDG-PET assist in further evaluation and staging.

Management of adrenocortical carcinoma (ACC) is challenging and requires a multimodal approach. Surgery with complete tumor resection (R0) is the primary curative option, especially for localized disease. Adjuvant therapies like mitotane and EDP-based chemotherapy are used in high-risk or advanced cases, though with limited efficacy. Radiation and emerging targeted or immune-based therapies are under investigation, with clinical trials offering hope for future advancements.

"Adrenocortical Carcinoma- Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Adrenocortical Carcinoma pipeline landscape is provided which includes the disease overview and Adrenocortical Carcinoma treatment guidelines. The assessment part of the report embraces, in depth Adrenocortical Carcinoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Adrenocortical Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Adrenocortical Carcinoma R&D. The therapies under development are focused on novel approaches to treat/improve Adrenocortical Carcinoma.

Adrenocortical Carcinoma Emerging Drugs Chapters

This segment of the Adrenocortical Carcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Adrenocortical Carcinoma Emerging Drugs

• CY-101: Cytovation

CyPep-1 is a proprietary first-in-class targeted tumor membrane immunotherapy engineered to selectively target cancer cells. Administered by intratumoral injection, CyPep-1 eliminates cancer cells by forming pores in the plasma membrane, releasing cancer specific antigens to the immune system, promoting an inflammatory microenvironment, and inducing a systemic, tumor-specific immune response. A synthetic peptide, CyPep-1 has been designed for easy and scalable manufacturing and is highly stable – an uncommon feature in these molecules.  Currently, the drug is in Phase II stage of its clinical trial as per the Company Pipeline for the treatment of Adrenocortical Carcinoma.

 Further product details are provided in the report……..

 

Adrenocortical Carcinoma: Therapeutic Assessment

This segment of the report provides insights about the different Adrenocortical Carcinoma drugs segregated based on following parameters that define the scope of the report, such as:

• Major  Players in Adrenocortical Carcinoma
• There are approx. 3+ key companies which are developing the therapies for Adrenocortical Carcinoma. The companies which have their Adrenocortical Carcinoma drug candidates in the most advanced stage, i.e. Phase II include, Cytovation.

 

Phases

DelveInsight’s report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

Adrenocortical Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

 

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

 

Adrenocortical Carcinoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Adrenocortical Carcinoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Adrenocortical Carcinoma drugs.

 

Adrenocortical Carcinoma Report Insights

• Adrenocortical Carcinoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

 

Adrenocortical Carcinoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Adrenocortical Carcinoma drugs?
• How many Adrenocortical Carcinoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Adrenocortical Carcinoma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Adrenocortical Carcinoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Adrenocortical Carcinoma and their status?
• What are the key designations that have been granted to the emerging drugs?